Please ensure Javascript is enabled for purposes of website accessibility
Taylor Carmichael

Taylor Carmichael


Taylor Carmichael is a former attorney and filmmaker. He's the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.

Recent articles


How Has Disney Stock Done Since January?

It's been a wild ride for the House of Mouse in 2020.


If You Invested $10,000 in Teladoc in January, This Is How Much You'd Have Now

The stock has done quite well for shareholders in 2020.


2 Stocks I Can't Wait to Buy When the Market Crashes Again

These investments have paid off since March's meltdown. Here's why another correction will bring attractive prices.


These 2 Stocks Have Doubled and Still Have Room to Grow

Silvergate Capital and fuboTV are both rocking in 2020, and each has plenty of potential to keep going in 2021.


These Were the 10 Best Healthcare Stocks of 2020

The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?


One Big Danger for Snowflake Investors

The stock is richly valued, and insiders will soon be able to sell.


If You Invested $10,000 in Arcturus in January, This Is How Much You'd Have Now

Shares of the mRNA biotech have been soaring in 2020.


Forget FAANG, Buy These 2 Unstoppable Stocks Instead

While tech stocks are overvalued, these investments have triple-digit revenue growth and incredible upside over the next decade.


Up 1,000% in 2020, Is Co-Diagnostics Stock Still a Buy?

The company has unbelievable top-line growth right now, and has profit margins over 60%. Will the stock continue to ride high once the world is vaccinated?


AstraZeneca COVID-19 Vaccine Achieves 70% Efficacy

The British pharmaceutical giant submits its phase 3 data to a peer-reviewed journal, the first company to do so.


How Did Trillium Stock Perform in 2020?

The micro-cap has shot up an incredible 1,400% this year.


Is Novavax Still a Buy After Jumping 3,000%?

The No. 1 stock of 2020 still has a lot of room to run... and a lot of room to fall.


Why Is Everybody Talking About GrowGeneration?

The marijuana stock is up 778% so far in 2020.


Why in the World Is Retractable Technologies Stock Up 566%?

Sales jumped 132% in the most recent quarter, as demand for the company's syringes have skyrocketed.


Why Is Everybody Talking About Jumia Stock?

The bulls think it might be the next Sea Limited or MercadoLibre. The bears see horrible profit margins and revenues going backwards.


Nano-X Stock Is Heading Higher

As we close in on Dec. 3 -- the day Nano-X will demonstrate its device to the Radiological Society of North America -- the bulls are charging and the shorts are fleeing. The stock jumped 17% on Monday.


2 E-Commerce Stocks That Are Outperforming Amazon

Shareholders of Sea Limited and Farfetch dramatically outdid Amazon owners in 2020. What's going on?


What Are the Odds That Novavax's Coronavirus Vaccine Is 90% Effective?

Pfizer and Moderna have reported vaccine efficacy of over 90%. What should Novavax investors expect?


Amarin vs. the Generics: Who Will Win?

After Amarin lost its patent rights in the U.S., the stock crashed overnight. Investors might want to stay optimistic.

GettyImages-1159049959 (1)

These 2 Under-the-Radar Stocks Are Great Buys Right Now

Freshpet and Afterpay have been stomping the market for years.